Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Published: January 12, 2017
Primary Outcome Measures
- Progression Free Survival Rate at 6 Months [ Time Frame: patients progression free at 6 months ] [ Designated as safety issue: No ] This is the percentage of patients alive and progression-free at 6 months from initiation of treatment.
Secondary Outcome Measures
- Response Rate [ Time Frame: from time of enrollment to time of best response or death from any cause, whichever came first up to 100 months ] [ Designated as safety issue: No ] Response was assessed by the RECIST criteria (version 1.0). Per those criteria, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
- Overall Survival [ Time Frame: from time of enrollment to death from any cause. Patients still alive at study end were censored with a minimum follow up of 6 months. ] [ Designated as safety issue: No ] Overall survival was measured from time of initiation of treatment to death from any cause
- Inclusion Criteria:
- Patients must have histologically proven malignant mesothelioma (epithelial, sarcomatoid, or mixed subtype) not amenable to curative surgery or radiotherapy. Eligible sites of origin include the pleura, peritoneum, and tunica vaginalis.
- Patient’s disease must not be amenable to curative treatment with surgery. Evidence of gross unresectability will include but not be limited to direct extension into the chest wall, mediastinal or hilar lymphadenopathy, pulmonary or cardiac function that is inadequate to tolerate resection, and sarcomatoid or mixed histology.
- Patients must be > 18 years old 5.2.4 Patients must have measurable disease.
- Adequate organ function and functional status
- Exclusion Criteria
- General Medical Concerns
- Patients must not be pregnant or breast feeding
- No “currently active” second malignancy other than non-melanoma skin cancer.
- Patients are not considered to have a “currently active” second malignancy if they have completed therapy and have a less than 30% risk of relapse
- No uncontrolled intercurrent illness including but not limited to: active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric/social situations that would limit compliance with study requirements.
- No HIV positive patients receiving combination anti-retroviral therapy because of possible pharmacokinetic interactions with study medications.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other agents used in the study.
- Inability to interrupt aspirin or other non-steroidal medication for a 5 day period
- Bevacizumab-Specific Concerns
- Patients with brain metastases are excluded 5
- History of myocardial infarction or CVA (stroke) within 6 months of study entry
- Evidence of bleeding diathesis or coagulopathy. Patients on therapeutic doses of coumadin are eligible as long as the INR is maintained in the range of 2-3 and there is no evidence of active bleeding
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
- Urine protein:creatinine ratio less than 1.0 at screening
- Serious, non-healing wound, ulcer, or bone fracture